P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: TAR-200 in patients with Bacillus Calmette–Guérin-unresponsive high-risk non–muscle-invasive bladder cancer: Results from SunRISe-1 study

Prostate-specific antigen dynamics from the phase 3 EMBARK trial: A post hoc analysis

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: The next generation trial: Assessing F-PSMA-1007 PET and MRI in primary staging of prostate cancer patients

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Pivotal Results from BOND-003: A Phase 3, Single-arm Study of Intravesical Cretostimogene Grenadenorepvec for the Treatment of High Risk, BCG-Unresponsive Non-Muscle Invasive Bladder C

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: SWOG S1011 – Subgroup analysis of the Phase III Surgical Trial to Evaluate the Benefit of a Standard Versus an Extended Lymphadenectomy Performed at Time of Radical Cystectomy for Muscl

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Apalutamide and androgen deprivation therapy for the treatment of high-risk localized prostate cancer following radical prostatectomy in Apa-RP: a multicenter, open-label, single-arm ph

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: HIFI trial: HIFU vs Radical prostatectomy for localized Prostate cancer in 3328 cases. Final results.

Third interim analysis (IA3) of the DARolutamide ObservationaL (DAROL) study in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC)

Accuracy of FDG-PET scan in primary testicular seminoma: Analysis from SEMS trial

TRUCE04: A Phase II Clinical Trial of RC48 for High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) (NCT05495724)

A Phase II trial of intravesical Gemcitabine and Docetaxel (GEMDOCE) in the treatment of BCG-naïve non-muscle invasive urothelial carcinoma of the bladder

Avelumab first-line maintenance for advanced urothelial carcinoma: long-term outcomes from JAVELIN Bladder 100 in subgroups defined by first-line chemotherapy regimen and analysis of overall survival from start of first-line chemotherapy

A randomized clinical trial comparing focal ablation and radical prostatectomy in patients with unilateral clinically significant prostate cancer. Intention to treat analysis at two-year follow-up.

P2s: Paradigm-shifting, Practice-changing Clinical Trials in Urology: Efficacy of [177Lu]Lu-PSMA-617 versus ARPI change in taxane-naive patients with metastatic castration-resistant prostate cancer by pre-randomization ARPI (PSMAfore)

ARV-766, a PROTAC androgen receptor (AR) degrader, combined with abiraterone in novel hormonal agent (NHA)-naïve metastatic prostate cancer: phase 1 cohort (part C) of a phase 1/2 study